PRO-CAR-T: A study to design and test a tool to gather information from patients after CAR-T therapy

This trial aims to design and test a digital tool which will gather self-reported information from blood cancer patients about their health after CAR-T therapy.

You can share the following ISRCTN.com Identifier with your medical team so they can find out more about the trial: ISRCTN11232653

Trial aim and background  

Chimeric Antigen Receptor T-cell (CAR-T) therapy is a new cancer treatment which uses the body’s own immune cells to recognise and kill cancer cells. It is very promising but has a number of side effects which can be serious. More information about these side effects is needed so that they can be appropriately treated. One way of gathering this information is through patient-reported outcomes (PROs) which can be done by patients filling out paper questionnaires, but increasingly they are being completed electronically. The aim of this study is to establish a digital tool so that this can be done for CAR-T treatments. 

Patients, family members and healthcare professionals will help the researchers to co-design the digital system. Once developed, its usability will be assessed, and then it will be introduced into clinical settings. Patients will use the digital system before, during, and 12 months after receiving CAR-T therapy. 

Who can enter 

For the initial stages of the study patients who are receiving CAR-T therapies, their family members and healthcare professionals are eligible for this trial. 

In the later stages adults with diffuse large B-bell lymphoma (DLBCL) who are eligible for CAR-T therapy may be eligible for the trial.

Locations 

Recruitment is taking place at the University Hospitals Birmingham NHS Foundation Trust, Birmingham

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://www.isrctn.com/ISRCTN11232653

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.